-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network July 20, July 16, Jincheng Pharmaceutical announced that it received a holding subsidiary of Guangdong Jincheng Jinsin notice, it obtained the Approval of the State Drug Administration issued on the injection of cephalosporine sodium 2.4 modified new drug "drug clinical trial approval notice", will carry out new adaptation clinical trials.
-meter net data show that in 2019 China's public medical institutions terminal cephalosporine sales of 4.125 billion yuan.
the basic condition of the drug Cefazolin Sodium is the first generation of cephalosporins, antibacterial spectrum, has been approved for the treatment of sensitive bacteria caused by respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, septicaemia, infectious endocarditis, liver and bile system infections, reproductive system infections and perioperative prevention of infections. According to
-minnet data, sales of cephalosporine in terminals in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as Public Medical Institutions in China) in 2019 were 4.125 billion yuan, up 2.14% year-on-year.
, Shenzhen China Resources nine new accounted for 80.56 percent of the market share, Shenzhen Lijian Pharmaceuticals accounted for 7.71 percent, Guangdong Jincheng Jinsu accounted for 3.33 percent.
China's public medical institutions terminal cephalosporine sales (units: 10,000 yuan) the current domestic market cephalosporine products are injected with cephalosporine sodium, injection with sodium cephalosporinin, injection of cephalosporine sodium / sodium chloride injection, injection with cephalosporine sodium manufacturers as many as 74, the competition is very fierce.
the competitive pattern of cephalosporine jinjin has been approved for production in 3 product regulations, the declared injection of cephalosporine sodium in line with the registration requirements of 2.4 types of improved new drugs.
inquiries, at home and abroad have not been approved with the same product "jaw facial gap infection" indications, the global new indications.
.